PROCEPT BioRobotics [PRCT] — Research

Tier-2 memo · as of 2026-07-29 · framework v1.5.1 Spot $18.09 (2026-07-28 close) · 56,918,844 shares · market cap $1,029.7m · net cash $194.0m · EV $835.7m Archetype: INFLECTION · SIC 3841 (Surgical & Medical Instruments) · Sub-sector: SMID MedTech

This memo issues no position verdict. It scores Criteria and outputs an analysis. The book decides.

0. Why this name was flagged, and what the screen got wrong

The Tier-1 screen ranked PRCT the top healthcare name in a 9,885-name universe on a +53.7pp valuation margin: a 60.1% demonstrated revenue CAGR against a 6.5% required CAGR at a $1.0bn market cap and 2.6x EV/Sales.

Every number in that record checks out arithmetically (Section 1). The problem is what "demonstrated" means. 60.1% is the three-year CAGR from FY2022 ($75.0m) to FY2025 ($308.1m). It is a rear-view mirror pointed at a period the company has since publicly disowned:

(Source: XBRL RevenueFromContractWithCustomerExcludingAssessedTax, CIK 0001588978; Q4 derived as FY minus the three filed quarters and cross-checked against the Q4'25 earnings release income statement, which prints $76,383k exactly.)

The screen's headline CAGR is ~3x the rate the business currently runs at and ~2x what it guides. That is not an error in the screen — it is the screen doing what it was asked. It is the reason Tier 2 exists.

And it gets worse before it gets better, because a material slice of the FY2023–FY2025 growth was not consumption at all. Management said so, on the record, on 2026-02-25.

1. Screen-input validation against primary filings

Per the brief, every screen input was re-derived from the source. No discrepancies found.

Scale cross-check (net income ÷ shares ≈ filed EPS). FY2025 net loss $95,572k ÷ 55,544k weighted shares = $(1.72); the filed FY2025 EPS is $(1.72). Q1'26: $31,638k ÷ 56,511k = $(0.56); filed $(0.56). Scale is confirmed to the cent. Single class of common stock — no dual-class aggregation problem.

Balance-sheet completeness. PRCT holds no marketable securities; the Q1'26 balance sheet shows cash and cash equivalents only, plus $3,038k restricted cash (non-current) that the screen correctly excluded. There is no hidden investment portfolio and no revolver draw. Long-term debt is a single $51.7m carrying-value facility, non-current, with $0 current portion.

One flag the screen itself raised and nobody acted on: data_quality_ok: false. That flag was not about any of the figures above — all of which are right. It is worth noting only because the record shipped a top-of-universe ranking with a data-quality flag set to false and no attached reason.

2. The mechanism — and the accounting question the brief asked

PRCT sells the AQUABEAM and HYDROS robotic systems for Aquablation therapy, a waterjet resection of the prostate for BPH. The model is capital equipment plus a single-use disposable handpiece per procedure, plus service. The brief's question — is the growth installed-base compounding or front-loaded system sales? — has a precise, disclosed answer, and it is not the one the razor/razorblade framing implies.

2.1 The revenue split is disclosed quarterly (but not annually)

(Q1'26 10-Q, Revenue note, R47; identical figures in the 2026-04-29 earnings release.)

So the recurring line grew 16.2%. Not 60%. Sixteen.

The deceleration in that line is violent and recent:

A disclosure asymmetry worth naming: the by-type disaggregation appears in every 10-Q and every earnings release, but neither the FY2024 nor the FY2025 10-K contains a revenue disaggregation note — I checked the FilingSummary.xml R-file inventory of both; the FY2025 10-K has no "Revenue" note and no "Disaggregation of Revenue" detail at all. It is not a Twist-style retirement (it was never there in the 10-K), but it means an investor reading only the annual report cannot see the system/consumable split. It has to be assembled from quarters.

2.2 The channel: management's own admission

From the Q4'25 release (2026-02-25), CEO Larry Wood, verbatim:

"…we successfully reduced field inventory levels and eliminated end-of-quarter purchasing incentives, which led to a fourth quarter revenue shortfall but improved handpiece average selling price by approximately 5%."

And, quantifying it:

"Historically, handpiece unit sales exceeded procedure volumes by approximately 8% to 16%. Going forward, we expect handpiece unit sales and procedure volumes to be closely aligned."

On the call, elaborating (Q4'25 earnings call, 2026-02-25):

"We eliminated the historical practice of providing discounts on bulk purchases, particularly at the end of the quarter." … "Customers had become accustomed to purchasing large quantities of handpieces and receiving bulk discounts in the final weeks." … "When we did a deep review of that, I just didn't think it made sense for us on a go-forward to be running that practice."

CFO Kevin Waters, on how much sat in the channel:

"Given current procedure trends, average customer inventory just a little over one month to seven weeks."

This is the finding. The "recurring handpiece revenue" that made PRCT look like a compounding razor/blade story was running 8–16% ahead of actual procedures, sold in end-of-quarter bulk at a discount into customer storerooms. It is a smaller-scale, self-disclosed cousin of the Applied Optoelectronics pattern the brief cites — except PRCT disclosed it itself, and the disclosure is what broke the stock.

The unwind is visible in the units:

Q4'25 is the clean picture of a destock: procedures +69%, handpieces +7%. Q1'26 at ~95% says the unwind is mostly but not entirely done — a full run-rate is 100%.

2.3 The deeper problem: there is no utilisation deepening

PRCT discloses US installed base and US procedures quarterly. Divide one by the other:

Annualised: FY23 68.5, FY24 67.6, FY25 70.9 procedures per system per year.

Three years, zero deepening. Every incremental procedure comes from a new box, not from existing customers doing more. That is the difference between an installed base that compounds and one that is merely linear in placements — and PRCT's is the latter. A razor/blade model whose blade attach rate per razor is flat is, economically, a capital-equipment company with a high-margin service annuity attached.

And placements are decelerating: 148 systems (FY23) → 190 (FY24, +28%) → 213 (FY25, +12%) → 47 in Q1'26 vs 42 in Q1'25 (+12%). US ASP for a new HYDROS is ~$485,000 (Q1'26 disclosure), against a US installed base of 765. Management sizes the US TAM as "approximately 8.0 million patients" and "approximately $30 billion" — but the system TAM is a count of US urology sites doing hospital-based resective BPH surgery, and PRCT does not disclose that denominator anywhere in the 10-K. The finite-hospital-TAM question the brief raised cannot be answered from the filings. See Section 6.

The mention-frequency work makes the same point from a different angle: "utilization" was said 3 times in the Q4'23 release and has effectively vanished since (Section 4). On the Q4'25 call, asked directly about it, the CEO answered: "Utilization is highly variable, and I think, again, what we're focused on is procedure growth."

2.4 What Q1'26 actually shows about the forward path

• US procedures were 12,200 in Q1'26 — identical to Q4'25's 12,200, sequentially flat, while the installed base went 653 → 718 → 765 (+17% across the two quarters).
• FY26 guidance requires US procedure growth of 39–48%, i.e. 60,200–64,100 procedures against FY25's 43,300. Q1'26's 12,200 annualises to 48,800 (+12.7%). Applying FY2025's own Q1 seasonal share (9,300 ÷ 43,300 = 21.5%) to Q1'26's 12,200 implies a full year of ~56,700 (+31%) — below the low end of the guide.
• Same arithmetic on revenue: FY2025 Q1 was 22.4% of the year; Q1'26's $83.1m at that share implies ~$371m, below the $390m guidance floor. The guide requires Q2–Q4 to average $105.6m, i.e. +27% off the Q1 base.

None of this is a prediction. It is the arithmetic of the guide against the one quarter reported under it, and it is what Q2'26 on 4 August will settle.

3. Reimbursement — resolved, and it is not the bottleneck

The brief asked whether reimbursement gates adoption. It did; it no longer does.

• Aquablation moved from Category III CPT 0421T to Category I CPT 52597, effective 1 January 2026.
• The 2026 Medicare PFS assigned it 16.14 total RVUs, ≈$540 national average physician payment.
• The 2026 OPPS/ASC final rule assigned CPT 52597 to APC 5377 — i.e. an ASC payment pathway now exists.

A Category I code plus an ASC APC is the single largest structural reimbursement upgrade this product could receive, and it landed at the start of the very year in which growth decelerated to +20%. The bull case cannot be "reimbursement is coming." It came.

Management is also explicitly not leaning on the ASC channel near-term. Asked about ASC capability on the Q4'25 call, the CEO: "Certainly, for the long-term plan, that's going to become part of our story as we go through time… I don't think it's something that's so much of a near-term thing for us." Consistently, "ambulatory surgery" appears zero times across all ten quarterly earnings releases from Q4'23 to Q1'26.

The honest reading: the ASC pathway is a real 2027+ optionality that is currently unmodelled and unpromoted — which is a different and better thing than a driver being counted on and not arriving.

4. Transcript / disclosure mention-frequency over time

Corpus: the ten quarterly results releases filed as 8-K Exhibit 99.1 on EDGAR, Q4'23 → Q1'26, boilerplate tail (Non-GAAP / Forward-Looking / About) truncated. This is a primary-source, exactly reproducible corpus (scripts/prct_mentions.py). It is press releases, not call transcripts — stated plainly rather than implied, because the two are not interchangeable.

What it says.

1. "Utilization" is the disappeared metric. Three mentions in Q4'23; one mention in the following nine quarters combined. It vanished from the narrative over exactly the period in which — per Section 2.3 — it stopped improving. This is the single most diagnostic row in the table.
2. Q4'25 is a discontinuity, not a bad quarter. "Handpiece" 3→13, "procedure" 0→9, first-ever appearance of "field inventory" and "realign", release length +39%. A company rewriting how it describes its own revenue.
3. "Install base" stayed constant at 1–2 mentions throughout — the metric that kept working kept being mentioned at a steady, low rate. There is no promotional inflation of the installed-base number.
4. "Ambulatory surgery": zero, always. Confirms Section 3 — the ASC pathway is not being sold to investors.

5. Product-cycle intelligence

Competitive set (context, not modelled): Teleflex UroLift, Boston Scientific Rezūm, Olympus iTind, and conventional TURP/HoLEP. PRCT's clinical differentiation is size- and surgeon-independence, supported by ~250 peer-reviewed publications (Q1'26 release, up from ~150 in the Q4'25 release). No competitor entered the waterjet modality during the period reviewed; the deceleration is not visibly a share-loss event.

6. What the sources cannot support

Stated explicitly rather than filled in:

1. The system TAM denominator. PRCT sizes the patient market ($30bn, 8.0m patients) but discloses no count of target US urology sites. With 765 US systems placed, whether that is 15% or 60% of the reachable site TAM is unknowable from the filings, and it is the single most important input to whether placement growth of +12% is early-innings or saturation. Not inferable; not inferred.
2. The size of the remaining field-inventory overhang. "A little over one month to seven weeks" of customer inventory and a 95% handpiece:procedure ratio bound it loosely. The dollar amount still to unwind is not disclosed.
3. Consensus estimates. Alpha Vantage's shared 25/day quota was exhausted at the time of this run. Consensus Criteria is INDETERMINATE and blocks nothing. External sell-side anchors that were verifiable: UBS $20 (cut to Neutral, July 2026) and Truist $25 (Hold, cut from $30, July 2026).
4. A WATER IV readout date. None is disclosed. No date is asserted anywhere in this memo.
5. Q2'26 results. Not filed. Everything forward here is guidance and arithmetic, and 4 August settles it.
6. The screen's 22.8x exit multiple peer set (exit_multiple_peer_n: 97, basis GROWTH_MATCHED). The constituent list is not in the screen record and could not be re-derived here. The Valuation section therefore leans on a sales-basis cross-check anchored on PRCT's own current multiple, which needs no peer set at all.
7. Securities litigation exposure. Multiple securities class actions were filed in July 2026 on behalf of purchasers of PRCT common stock between 28 February 2024 and 25 February 2026, alleging materially false or misleading statements about the discounting programme and customer overstocking. No 8-K disclosing them had been filed with the SEC as of 2026-07-28, no damages estimate exists, and none is modelled. Reported here as a named risk, not a quantified one. The claim's substance is the same fact pattern Section 2.2 documents from the company's own disclosure.

7. Criteria scoring

Quality Criteria — PASS (BINDING)

Archetype INFLECTION, correctly assigned (GM 64%, operating margin negative and expanding, growth >18%).

Flag 1 — the margin expansion stalled in the most recent quarter. Q1'26 operating margin −39.2% against Q1'25's −39.7%: +0.5pp, not the +4.8pp the TTM shows. FY26 guidance (revenue $400m, GM 65%, opex $350m) implies −22.5%, an +11.2pp step — entirely un-evidenced by the one quarter reported under it.

Flag 2 — the recurring line grows at 16.2%, below the 18% threshold the criterion uses. Total revenue clears it at 20.2% only because system sales grew 20.8%. If the criterion were applied to the recurring revenue alone it would not pass.

Flag 3 — operating cash burn re-accelerated. FY25 burn $49.0m (improved from FY24's $99.2m), but Q1'26 alone burned $38.1m against Q1'25's $17.0m. Cash fell $286.5m → $245.6m in a single quarter. Balance-sheet ratios are otherwise stable (DSO 103 days vs 102 a year ago; inventory 244 days vs 245).

Valuation Criteria — PASS (BINDING)

Full working in PRCT_Valuation.md. Required 5-year revenue CAGR at $18.09: 7.4% (WACC 11%; 6.5% at WACC 10%, reproducing the screen). Assumption-light cross-check at an unchanged 2.6x exit sales multiple: 11.0%. Margin against the most conservative honest comparator — the recurring handpiece line at +16.2% — is +5.2pp; against FY26 guidance (+30% mid) it is +19.0pp.

Downside Criteria — MEASURED, logged

Named cause and probabilities in PRCT_Trade_Construction.md §4. Headline: the destock is not finished and procedure growth — not just shipments — decelerates; FY26 lands near $370–380m; $17–18, roughly spot. Severe case, requiring an equity raise into a depressed price: $9–11, −40% to −50%. No going-concern case is argued: $194.0m net cash, $51.7m non-current debt, FY26 guided adjusted-EBITDA loss $17–30m.

Liquidity Criteria — PASS (equity) / PASS AT SMALL SIZE ONLY (options) (BINDING)

Consolidated ADV (Alpaca SIP, 81 sessions to 2026-07-28): $31.5m/day, 1.37m shares/day. Chain pulled live — see PRCT_Trade_Construction.md §3 for strike-level open interest and quoted size.

MEASURED Criteria

8. The analysis in one paragraph

PRCT is a real product with a real installed base, a resolved and recently upgraded reimbursement pathway, and a price that has fallen 82% from its high to 2.6x sales — the 0.5th percentile of its own trading history. At that price the implied path is undemanding: 7.4% revenue CAGR for five years, or 11.0% if you refuse to assume any multiple expansion at all, against a business growing 20% and guiding 30%. That is the bull case, and it is arithmetically sound. Against it: the 60% growth that put this name at the top of the screen was partly 8–16% of channel fill that management has now eliminated; the installed base shows zero utilisation deepening in three years, so consumable growth is linear in placements and placements grew 12%; Q1'26 procedures were flat sequentially while the base grew 17%; the FY26 guide requires a Q2–Q4 average 27% above the Q1 base; margin expansion stopped in Q1'26; quarterly cash burn doubled; and a securities class action now alleges the discounting programme was concealed. The valuation margin is wide enough to survive all of that — which is exactly why the honest output is a scored analysis rather than a verdict, and why the 4 August print is the whole question.